F.I.R.S.T.™ Read More
1. The first stage isolates antibodies that recognise cancer cells better than they recognise healthy cells. In this so-called comparative screening stage, a large number (hundreds to tens of thousands) of antibodies that bind very specifically to different target structures are identified.
2. The second stage involves functional screening of the antibodies’ ability to kill cancer cells, i.e. their ability to inhibit the cancer cells’ biological activity, as well as the ability to activate the patient’s immune defence cells.
3. The third stage involves determining which target structures (antigens) the antibodies bind to. These may be both known and new target structures. This work is also important to the ability to protect the intellectual property in the biological material.
4. The fourth stage involves testing the studied antibodies and target structures in clinically relevant animal models. This is very important to determine tolerance and efficacy of the selected drug candidate in humans.